Regulatory Approval

Lupin and Natco Receive U.S. FDA Approval for Eribulin Mesylate Injection Generic

NSE

lupin

BSE

500257

Lupin Limited and its alliance partner Natco Pharma have received U.S. FDA approval for Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, a generic equivalent of Halaven® Injection. The approval expands the partnership’s oncology portfolio in the U.S. market and targets a product with estimated annual U.S. sales of USD 43.7 million.

PRICE-SENSITIVE TRIGGER

Event: U.S. FDA approval for Eribulin Mesylate Injection ANDA.

Type: Regulatory Approval

Impact: Positive

Immediate Effect: The approval enables commercialization of a generic oncology product in the U.S. market, strengthening Lupin’s specialty and complex generics portfolio.

Key Metrics:

Product: Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL)
Regulatory Authority: U.S. FDA
Reference Product: Halaven® Injection (Eisai Inc.)
Estimated U.S. Market Size: USD 43.7 Million annually
Dosage Form: Single-Dose Vials

Highlight:

Key Highlight: U.S. FDA approval received for a generic product targeting a USD 43.7 million U.S. market opportunity.

What Happened ?

Lupin Limited and Natco Pharma announced that the U.S. Food and Drug Administration has approved Natco’s ANDA for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.

The product is bioequivalent to Halaven® Injection and is indicated for treatment of certain patients with metastatic breast cancer and unresectable or metastatic liposarcoma. The approval provides an opportunity for the companies to participate in a niche oncology market within the United States.

Key Details

Regulatory Approval and Product Opportunity:

U.S. FDA approved Natco’s ANDA for Eribulin Mesylate Injection.
Lupin participated through its alliance partnership with Natco Pharma.
Product is the generic equivalent of Halaven® Injection.
Approved dosage strength is 1 mg/2 mL (0.5 mg/mL) in single-dose vials.
Product is indicated for treatment of metastatic breast cancer after prior chemotherapy regimens.
Product is also indicated for unresectable or metastatic liposarcoma following anthracycline-containing therapy.
Approval strengthens the oncology and complex injectable portfolio in the U.S.
Commercial opportunity is supported by an estimated annual U.S. market size of USD 43.7 million.

Note:

The approval further expands Lupin’s presence in regulated markets and reinforces its strategy of building a portfolio of complex generic and specialty pharmaceutical products.

Risk Analysis

Summary:

While regulatory approval removes a key hurdle, commercial success will depend on market penetration, competitive intensity, pricing dynamics, and supply chain execution.

Key Risks:

Generic competition may impact pricing and market share.
Commercial launch timelines were not disclosed.
U.S. healthcare reimbursement and pricing pressure remain industry risks.
Market opportunity estimates may fluctuate over time.
Manufacturing and supply continuity remain important for sustaining revenue generation.

Worst Case Scenario:

Aggressive generic competition or pricing erosion could reduce the revenue opportunity despite regulatory approval.

Risk Level: Low

Company Commentary

Lupin and Natco have received U.S. FDA approval for Eribulin Mesylate Injection.
The approved product is bioequivalent to Halaven® Injection.
The approval supports treatment options for metastatic breast cancer and liposarcoma patients.
The product addresses a U.S. market estimated at USD 43.7 million annually.
Lupin remains focused on expanding its pharmaceutical portfolio across global regulated markets.
The company continues to strengthen its presence in complex generics, biotechnology products, and active pharmaceutical ingredients.

Official Exchange Filing: Lupin Limited